Retractable Technologies, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. The company designs, manufactures and markets safety syringes and other medical products. This unaudited filing covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods. VanishPoint syringes represented 80.5% of nine-month sales. The company reports one operating segment.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $10.34 million | $23.06 million | $29.31 million | $82.14 million |
| Gross profit | $4.32 million | $4.74 million | $7.57 million | $23.95 million |
| Gross margin | 41.8% | 20.5% | 25.8% | 29.2% |
| Operating income (loss) | $(0.94) million | $(0.69) million | $(8.71) million | $6.97 million |
| Net income (loss) | $(4.06) million | $5.39 million | $(6.94) million | $9.36 million |
| Net income (loss) per diluted share | $(0.14) | $0.16 | $(0.24) | $0.28 |
For the nine months, operating cash flow was $0.87 million, investing cash outflow was $10.41 million, and financing cash inflow was $1.08 million. Cash declined by $8.46 million to $11.26 million. At September 30, the company held $33.65 million in debt and equity securities, total current assets of $77.80 million, and total current liabilities of $9.26 million. Long-term debt, including its current portion, totaled approximately $1.61 million. Total liabilities were $82.09 million, including a $71.52 million TIA-related deferred liability. Total assets were $181.52 million and stockholders’ equity was $99.42 million.
Material changes versus the prior comparable periods
- Sales fell 55.2% in Q3 and 64.3% in the first nine months. Management attributed the decline chiefly to fewer COVID-19 vaccination-related orders, including the absence of prior U.S. government sales, and lower international demand.
- Nine-month operating results shifted from $6.97 million of operating income to an $8.71 million operating loss. Lower volume and higher manufactured-product cost per unit contributed to the loss. Q3 gross margin improved year over year, but gross profit was lower.
- Unrealized investment losses were $6.54 million in Q3 and $11.30 million for the first nine months, versus $0.62 million and $1.19 million, respectively, in 2022. The nine-month period also included a $5.57 million gain on sale of equity securities.
- Cash and cash equivalents decreased from $19.72 million at December 31, 2022 to $11.26 million at September 30, 2023, while investments rose from $29.66 million to $33.65 million. The company said investment purchases materially reduced cash.
- Management reported approximately $1.9 million in employee-related cost savings for the first nine months following workforce reductions in 2022 and March 2023. Sales and marketing expense increased approximately 30.9% year over year for the nine-month period, reflecting sales efforts including travel, trade shows and sales representatives.
Outlook, risks and unusual items
- Management believes available cash, investments and expected operating income will fund short-term needs for at least 12 months from issuance of the statements, and says foreseeable long-term liquidity needs can be met. No specific revenue or earnings guidance is provided.
- Management says domestic unit sales increased in each quarter of 2023 after customers worked through vaccination-related inventory; it expects seasonal patterns to resemble pre-pandemic trends. It cautions that the timing and volume of international orders are uncertain and that future U.S. government orders cannot be predicted.
- Approximately 90% of products in the first nine months came from Chinese manufacturers; China-produced goods represented about 91% of Q3 products. Disruption could require finding alternate suppliers or increasing domestic production. Management also cites demand, tariffs, supplier costs, production volumes, pricing, patent protection and market competition as risks.
- The company received an approximately $8 million state tax refund in July 2023. It reports that all equipment was received, required TIA-funded construction was completed, and all reimbursement requests were submitted; no additional TIA expansion amounts are expected to be submitted or collected. TIA income recognized in the first nine months was $4.48 million.
- A lawsuit against Locke Lord, LLP and Roy Hardin concerning prior legal representation is scheduled for jury trial on February 26, 2024. The filing describes claims for damages and other relief; the outcome is not specified.
- The company disclosed that CEO Thomas J. Shaw adopted a Rule 10b5-1 plan on August 22, 2023, allowing purchases of up to $800,000 of company stock from November 20, 2023 through November 19, 2024, subject to price parameters and possible earlier termination.
- Management concluded disclosure controls and procedures were effective as of September 30, 2023. The filing reports no material change to risk factors from prior reports.
Important facts for investors to verify
- Whether domestic and international sales recover as customers use existing inventory, and whether any new government orders occur.
- Investment holdings, fair-value changes and potential effects on reported earnings and liquidity.
- Customer concentration: three significant customers accounted for 55.0% of Q3 sales and 49.0% of nine-month sales.
- Reliance on Chinese manufacturers, supplier alternatives and the cost or feasibility of shifting production.
- Progress and potential outcomes in the February 2024 litigation, and any material financial effect.
- Liquidity assumptions, rebate estimates and the remaining TIA liability and related amortization.